The Goldman Sachs Group, Inc. 13D and 13G filings for Ligand Pharmaceuticals Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 5:34 pm Sale | 2024-09-30 | 13G | Ligand Pharmaceuticals Incorporated LGND | GOLDMAN SACHS GROUP INC GS | 52,350 0.300% | -1,129,581 (-95.57%) | Filing |
| 2024-02-12 7:42 pm Purchase | 2023-12-29 | 13G | Ligand Pharmaceuticals Incorporated LGND | GOLDMAN SACHS GROUP INC GS | 1,181,931 6.800% | 1,181,931 (New Position) | Filing |